uniQure N.V. - Ordinary Shares (QURE) News
Filter QURE News Items
QURE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
QURE News Highlights
- QURE's 30 day story count now stands at 10.
- Over the past 20 days, the trend for QURE's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about QURE are GENE, AMT and IX.
Latest QURE News From Around the Web
Below are the latest news stories about UNIQURE NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment. The equity awards were approved by the Company’s board of directors on February 23, 2023 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c |
Are Options Traders Betting on a Big Move in UniQure (QURE) Stock?Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately. |
uniQure to Participate in Multiple Upcoming Industry Conferences in MarchLEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Cowen Annual Healthcare Conference, March 6 – 8, 2023 Boston, MA Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in one-on-one i |
uniQure Stock Trying To Close In On Key Technical MeasureA Relative Strength Rating upgrade for uniQure shows improving technical performance. Will it continue? |
UniQure (QURE) Tops Q4 Earnings and Revenue EstimatesuniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington’s disease – clinical update from U.S. Phase I/II trial expected in second quarter 2023 ~ ~Hosted virtual investor event featuring AMT-260 in refractory temporal lobe epilepsy - expected to enter clinical development in second half of 2023 ~ ~Expanded pipeline with in-licensing of AMT-162 for SOD1 ALS - plans to in |
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and generate elevated and sustained factor IX levels for years after a one-time infusion ~ ~ 18-month data support the ongoing benefit of HEMGENIX® ~ ~ HEMGENIX® is approved for adults with hemophilia B in the United States, European Union and European Economic Area ~ LEXINGTON, Mass. and |
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)Global biotechnology leader CSL (ASX: CSL) today announced the publication in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8) results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb). HEMGENIX® is the first and only gene therapy approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeate |
The Petri Dish: Blindness drug approved; Moderna strikes gene-editing dealApellis' new drug is the only FDA-approved treatment for geographic atrophy, a leading cause of blindness. |
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~ ~ Approval marks uniQure’s second internally-developed and manufactured gene therapy to achieve licensure in the European Union ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NA |